Search
AZD7442
go.drugbank.com/drugs/DB15787Investigational[L15596] It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that of other vaccines.[L15591]
Luvometinib
go.drugbank.com/drugs/DB21696InvestigationalLuvometinib is under investigation in clinical trial NCT07004075 (FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration).
Diacetyl benzoyl lathyrol
go.drugbank.com/drugs/DB11260ApprovedIt is also reported to be a skin conditioning agent.
Mixtures: O HUI white-skin science white calming maskPF-03187207
go.drugbank.com/drugs/DB05746InvestigationalBased on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP. … The development of abnormally high IOP, due to blockage or malfunction of systems controlling the amount of fluid in the eye, is believed to be one of the principal causes of glaucoma.
Sonpiretigene isteparvovec
go.drugbank.com/drugs/DB17844InvestigationalDeveloped by Nanoscope Therapeutics, it is being investigated for vision restoration in advanced retinitis pigmentosa (RP).
Dobutamine
go.drugbank.com/drugs/DB00841ApprovedInvestigationalA beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery.
Synonyms: 3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-β-phenylethylamineBexotegrast
go.drugbank.com/drugs/DB16515InvestigationalThe compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and Pliant Therapeutics recently raised $100 million in Series C financing to support further clinical … PLN-74809 is a small-molecule that dually inhibits both α<sub>v</sub>β<sub>6</sub> and α<sub>v</sub>β<sub>1</sub> to treat both idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC
JSM 6427
go.drugbank.com/drugs/DB06139InvestigationalJSM 6427 is the first small molecule alpha5beta1 integrin receptor antagonist of its kind to be developed.